ArticleOncoimmunology
Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 3 syntheses or guidelines pooled it, 85 citations in OpenAlex.
- The correlation between the influencing factors and efficacy of immune checkpoint inhibitor therapy: an umbrella meta-analysis of randomized controlled trials.Annals of medicine · 2023Pooled it
- Association of Personal Characteristics and Effectiveness of Immunotherapy in Late-Stage Non-Small Cell Lung Cancer: A Systematic Review.JNCI cancer spectrum · 2022Pooled it
- Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis.Oncoimmunology · 2020Pooled it
- Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors.The oncologist · 2021Trial
- The brain-lung immunotherapy prognostic (BLIP) Score: a novel robust tool for prognostication in non-small cell lung cancer patients with brain metastases.British journal of cancer · 2026Article
- Atezolizumab Combined With Cisplatin Plus Vinorelbine as Adjuvant Therapy for Completely Resected NSCLC WithJTO clinical and research reports · 2026Article
- Article
- Article
- Evaluation of implementation of evolving practice patterns in the first-line treatment of patients with metastatic non-small cell lung cancer in Turkiye (ESTIMATE): a national, multicenter, retrospective, real-world evidence study.Future oncology (London, England) · 2025Article
- Pt-Au Nanoparticles in Combination with Near-Infrared-Based Hyperthermia Increase the Temperature and Impact on the Viability and Immune Phenotype of Human Hepatocellular Carcinoma Cells.International journal of molecular sciences · 2025Article
- Prognostic stratification through smoking status and cumulative smoking dose in advanced non-small cell lung cancer immunotherapy: a dose-dependent real-world analysis.Frontiers in oncology · 2025Article
- Cadonilimab as second-line therapy in immunotherapy-resistant squamous NSCLC: a case report and review.Frontiers in immunology · 2025Review
- Intersecting evidence: Bibliometric analysis and clinical trials illuminate immunotherapy in KRAS-mutation cancer: A review.Medicine · 2024Review
- Reprogramming exosomes for immunity-remodeled photodynamic therapy against non-small cell lung cancer.Bioactive materials · 2024Article
- Clinical and molecular significance of homologous recombination deficiency positive non-small cell lung cancer in Chinese population: An integrated genomic and transcriptional analysis.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024Article
- Utility of molecular markers in predicting local control specific to lung cancer spine metastases treated with stereotactic body radiotherapy.Journal of neuro-oncology · 2024Article
- Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with KRAS mutations: A network meta-analysis.The clinical respiratory journal · 2024Article
- PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer.Future oncology (London, England) · 2024Article
- Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway.Journal for immunotherapy of cancer · 2023Article
- Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 3 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.